Skip to content

Study · Not a test of the peptide alone · 2026

3 results

Energy-replenishing, mitochondria-targeted hydrogel microspheres mitigate sarcopenia via cellular senescence amelioration.

Bao W, Liu S, Du C, Liu J, Luo X, He Y, Huang D, Xu W, Lei Y, Huang W, Liao J

Journal of controlled release : official journal of the Controlled Release Society7 Jan 2026Cited by 1 (Europe PMC)

PMID41512967 (opens in a new tab)DOI10.1016/j.jconrel.2025.114595 (opens in a new tab)PepBankPUB-41512967
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome

    NMN@Lipo-s@AHM, an NMN hydrogel microsphere with SS‑31 targeting, significantly alleviated dexamethasone-induced mitochondrial dysfunction in muscle cells.

    In plain wordsIn cells, a hydrogel microsphere carrying NMN and SS‑31 eased mitochondrial dysfunction caused by dexamethasone in muscle cells.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseDexamethasone-induced mitochondrial dysfunction
    Study

    n: not reported in source

    dexamethasone-induced muscle cells
    Outcome group
    Mitochondrial function · Musculoskeletal

    Source sentences

    Summary
    the Energy-replenishing hydrogel microspheres significantly alleviated dexamethasone-induced mitochondrial dysfunction and senescent phenotypes in muscle cells

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  2. 02LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome

    NMN@Lipo-s@AHM, an NMN hydrogel microsphere with SS‑31 targeting, significantly alleviated dexamethasone-induced senescent phenotypes in muscle cells.

    In plain wordsIn cells, a hydrogel microsphere carrying NMN and SS‑31 eased senescent features caused by dexamethasone in muscle cells.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseDexamethasone-induced senescent phenotypes
    Study

    n: not reported in source

    dexamethasone-induced muscle cells
    Outcome group
    Aging markers · Musculoskeletal

    Source sentences

    Summary
    the Energy-replenishing hydrogel microspheres significantly alleviated dexamethasone-induced mitochondrial dysfunction and senescent phenotypes in muscle cells

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  3. 03LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism

    The hydrogel microsphere activated the AMPK-SIRT1-PGC1α signaling pathway, improving mitochondrial energy metabolism and cellular senescence.

    In plain wordsIn cells, a hydrogel microsphere carrying NMN and SS‑31 switched on the AMPK-SIRT1-PGC1α pathway linked to energy metabolism.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseAMPK-SIRT1-PGC1α pathway activation
    Study

    n: not reported in source

    dexamethasone-induced muscle cells
    Outcome group
    Mitochondrial function · Musculoskeletal

    Source sentences

    Summary
    the hydrogel microsphere regulates mitochondrial function by activating the "AMPK-SIRT1-PGC1α" signaling pathway

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.